Pilot Study Finds 30-Day Molecular Improvement in Prostate Health Following Intraprostatic Ozone Therapy, Tracked by the EpiSwitch® PSE Blood Test

BOCA RATON, Fla., Jan. 22, 2026 /PRNewswire/ -- Doctors Studio by Forum Health, LLC today announced pilot findings indicating that intraprostatic ozone therapy was associated with measurable molecular improvement in prostate health within 30 days, quantified by the EpiSwitch^® Prostate Cancer Detection (PSE) blood test. In this 10-patient cohort (ages 54–76), mean PSE probability scores decreased from 0.56 (±0.27) at baseline to 0.39 (±0.31) post-therapy—a relative reduction of approximately 31% (paired t-test, p=0.045; Cohen's d=0.69). Eight of ten patients (80%) showed individual decreases; the mean PSA fell by ~20% after normalization for a single age outlier.

The EpiSwitch^® PSE test is a validated, 94% accurate, blood-based assay that assesses 3D genomic conformations linked to clinically significant prostate cancer. The pilot used paired pre- and post-treatment PSE and PSA measures and included linear discriminant analysis, which demonstrated distinct clustering of pre- versus post-therapy molecular profiles.

"Men deserve better, faster feedback on whether an intervention is moving their biology in the right direction," said Lisbeth Roy, DO, Founder & CEO of Doctors Studio and co-author of the paper. "These early results suggest that precision molecular monitoring can help us personalize care pathways while we investigate promising adjunctive therapies. Our next step is a larger, multi-center evaluation with longer follow-up."

Intraprostatic ozone was administered transperineally (20 μg/mL gamma ozone; 40 mL total) using external landmarking to approximate the bilateral transitional and central zones. Thirty days later, patients repeated PSA and PSE testing. Marker-level patterns included directional changes in regions associated with extracellular matrix remodeling and gene regulation, aligning with the overall PSE score reductions.

"We observed coordinated molecular shifts over a short interval in most participants, findings that were both notable and encouraging," said Dr. Joe Abdo, second author of the paper. "The EpiSwitch PSE test provided a robust way to monitor molecular hallmarks of disease biology and treatment-associated change in real time. It was also a privilege to collaborate with the clinician-scientists at Doctors Studio, who exemplify what personalized molecular oncology can look like in everyday clinical practice."

Limitations noted by the authors include the small cohort (n=10), a 30-day observation window, and the exclusion of one older participant from some analyses due to statistical outlier status. The authors emphasize that ozone therapy is investigational in this context and that prospective, controlled studies are needed.

The full white paper, slide deck visuals (including the distributional change in PSE probability scores and LDA separation), and a summary are available here. A citable version is available here: https://zenodo.org/records/17634127

Media contacts:
For all media inquiries, email [email protected]

About Doctors Studio
Doctors Studio is a functional and regenerative medicine practice focused on personalized, root-cause care for men's health, including prostate wellness, sexual function, and performance. The clinic combines advanced diagnostics with science-based therapies and is home to the ProstaGen^™ Method, a two-phase roadmap to assessment and transformative treatment.

About Oxford BioDynamics
Oxford BioDynamics PLC (AIM: OBD) is a global biotech company advancing personalized healthcare by developing and commercializing precision medicine tests for life-changing diseases. Its flagship products are the EpiSwitch CiRT (Checkpoint Inhibitor Response Test) and EpiSwitch^® PSE (EpiSwitch Prostate Cancer Detection Test) blood tests. CiRT predicts how a patient will respond to immune checkpoint inhibitor therapies. PSE is a blood test that increases the predictive accuracy of a PSA test from 55% to 94% for detecting the presence or absence of prostate cancer.

OBD's proprietary EpiSwitch^® platform harnesses 3D genomic regulation biomarkers to develop molecular diagnostic classifiers for numerous indications, including predicting response to therapy, patient prognosis, disease diagnosis, and residual disease monitoring. For more information, please visit myOBDX.com.

Disclaimer
This pilot white paper is for educational purposes only and is not intended as medical advice. Ozone therapy in this context is investigational. Patients should consult their physicians and consider standard-of-care guidelines.

SOURCE Forum Health, LLC